Results 211 to 220 of about 1,411,950 (341)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review. [PDF]

Drug Des Devel Ther
Al Khzem AH, Wali SM.
europepmc   +1 more source

Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery [PDF]

, 2015
Yuxi Wang, Hang Zhang, Benoı̂t Gigant, Yamei Yu, Yangping Wu, Xi Chen, Qinhuai Lai, Zhao-ya Yang, Qiang Chen, Jinliang Yang   +9 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

A case study of the application of AI to early stage drug discovery. [PDF]

Sci Rep
Abdel-Rehim A, Soldatova LN, King RD.
europepmc   +1 more source

Drug Design and Discovery: Principles and Applications [PDF]

, 2017
Shu‐Feng Zhou, Wei-Zhu Zhong
openalex   +1 more source

Drug Discovery [PDF]

Chemical & Engineering News Archive, 2002
openaire   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Drug Discovery and Repurposing for <i>Coccidioides</i>: A Systematic Review. [PDF]

J Fungi (Basel)
Saeger S, Lozano S, Wiederhold N, Yu JJ, Lopez-Ribot JL, Hung CY.   +5 more
europepmc   +1 more source

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies [PDF]

, 2011
Diana W. Shineman, Guriqbal S. Basi, Jennifer L. Bizon, Carol A. Colton, Barry Greenberg, Beth Hollister, John Lincecum, Gabrielle G. Leblanc, Linda H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M. Refolo, David Riddell, Kimberly Scearce‐Levie, Patrick Sweeney, Juha Yrjänheikki, Howard Fillit   +17 more
openalex   +1 more source